Actinium Pharmaceuticals (ATNM) Ownership - Who owns Actinium Pharmaceuticals?

Key Takeaways

• ATNM is the ticker for Actinium Pharmaceuticals, Inc., a clinical-stage biotechnology company developing targeted radiotherapies for cancer.
• The company's core technology platform is Antibody Radiation Conjugates (ARCs), which combine cancer-targeting antibodies with radioactive isotopes to deliver radiation directly to tumor cells.
• Its lead programs include ATNM-400, Actimab-A, Iomab-B, and Iomab-ACT, targeting solid tumors and blood cancers such as acute myeloid leukemia (AML).
• As a clinical-stage company, Actinium has not yet received regulatory approval for any product and generates no commercial revenue, funding itself primarily through equity sales and partnerships.
• Actinium has a research collaboration with the National Cancer Institute (NCI) and a licensing agreement with Immedica for the commercialization of Iomab-B in Europe, the Middle East, and North Africa.

Introduction

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies intended to improve outcomes for cancer patients who have failed existing treatments. The company's approach combines the precision of antibodies with the cell-killing power of radiation, an emerging field known as radiopharmaceuticals. Investors follow ATNM primarily because of its differentiated pipeline of Antibody Radiation Conjugates (ARCs) and its positioning within the rapidly growing targeted radiotherapy market.

Company Overview and Business Model

Actinium Pharmaceuticals was incorporated in Delaware in 2013 and is headquartered at 100 Park Avenue in New York City. The company traces its focus on radiotherapies back to its founding, which sources cite around 2000, and it operates as a single-segment biotechnology business devoted to research and clinical development.

The company's business model is centered on discovering and developing novel radiopharmaceutical product candidates, then advancing them through clinical trials with the goal of securing regulatory approval or licensing partnerships. Like most clinical-stage biotechs, Actinium does not yet sell any products. Its financial profile reflects this stage of development: the company reported no product revenue and a net loss of approximately $33.9 million for 2025, with operations funded largely through equity offerings, grants, and licensing agreements.

Core Technology and Pipeline

Actinium's platform is built around Antibody Radiation Conjugates, which link a targeting antibody to a radioactive isotope such as Actinium-225 (Ac-225) or Iodine-131 (I-131). The antibody seeks out specific proteins on cancer cells, allowing the attached radiation to kill tumors while limiting damage to healthy tissue. The company's lead programs include:

• ATNM-400 – a first-in-class Ac-225 radioconjugate targeting a novel, non-PSMA antigen with preclinical activity across solid tumors including metastatic prostate cancer, non-small cell lung cancer, and breast cancer.
• Actimab-A – a CD33-targeted Ac-225 therapy being developed for AML and myelodysplastic syndrome (MDS), as well as a mechanism to enhance checkpoint inhibitor efficacy in solid tumors.
• Iomab-B – a CD45-targeted I-131 conditioning agent for bone marrow transplant in patients with relapsed or refractory AML.
• Iomab-ACT – a conditioning platform designed to improve access to cell and gene therapies such as CAR-T.

Partnerships and Competitive Positioning

Actinium holds a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to develop Actimab-A in AML and other myeloid malignancies. In 2022, the company licensed exclusive rights to commercialize Iomab-B in the EUMENA region (Europe, Middle East, and North Africa) to Immedica. The company also maintains a substantial intellectual property portfolio, citing roughly 250 patents and patent applications, including technology for cyclotron-based production of Ac-225.

Within the radiopharmaceutical field, Actinium competes against large pharmaceutical companies and smaller clinical-stage developers. Its market position is differentiated by a focus on novel, non-PSMA and non-SSTR targets, in contrast to many competitors concentrated on validated targets such as PSMA in prostate cancer.

Why Investors Follow ATNM

Actinium attracts attention because targeted radiotherapy is an area of growing clinical and commercial validation. The company's biology-driven approach seeks first-in-class targets with "pan-tumor" potential, which could address large patient populations across multiple cancer types. Its late-stage hematology programs, supported by clinical data across hundreds of patients, offer potential partnership and value-creation opportunities. The company's efforts to build an integrated supply chain, including internal manufacturing capabilities and proprietary isotope-production technology, are also viewed as strategic differentiators in a field where isotope supply has historically been a bottleneck.

Risks and Important Considerations

Investing in Actinium carries substantial risk typical of clinical-stage biotechnology. The company has no approved products, no commercial revenue, and has incurred losses every year since inception. Its future depends heavily on the success of clinical trials, which may fail or face regulatory setbacks. The company also requires additional financing to continue operations and development. Regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA) are uncertain, and the company faces intense competition from better-resourced pharmaceutical firms. Supply of radioactive isotopes, manufacturing scale-up, and reliance on third parties are additional operational risks. Investors should carefully weigh these factors against the company's longer-term potential.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Explore the AI Screener to discover opportunities aligned with your approach.

Conclusion

Actinium Pharmaceuticals is a clinical-stage pioneer in targeted radiotherapy, distinguished by its Antibody Radiation Conjugate platform, novel target selection, and a pipeline spanning solid tumors and hematologic malignancies. While the company has yet to generate product revenue or secure regulatory approval, its differentiated technology, partnerships with institutions like the NCI, and position within the expanding radiopharmaceutical market keep it a notable name for investors evaluating the oncology biotechnology space.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations